News | October 25, 2021
Biocon reports a consolidated net profit of Rs. 138.3 crore in Q2FY22
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
Lilly will continue to maintain its existing operating model for the remaining portfolio of products
The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all
The company does not expect the outcome of this inspection to impact its plans
At present 18 per cent of the local pharmaceutical market is under government's price control
The segment delivered strong sales growth of 20% YoY
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
The company is eligible for 12 months exclusivity from launch
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
Subscribe To Our Newsletter & Stay Updated
